Ignite Creation Date:
2025-12-24 @ 11:31 PM
Ignite Modification Date:
2025-12-24 @ 11:31 PM
Study NCT ID:
NCT07046156
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-07-01
First Post:
2025-06-23
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Treatment of Overactive Bladder With Anticholinergic Agents
Sponsor:
Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital
Organization:
Study Overview
Official Title:
Evaluation of Anticholinergic Treatment Response and Predictive Factors in Pediatric Overactive Bladder
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2025-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to evaluate the efficacy and adverse effect incidence of three different anticholinergics (oxybutinin, propiverine, and tolterodine) that are used in children with overactive bladder.
Detailed Description:
A total of approximately 150 patients with overactive bladder will be evaluated retrospectively. Clinical and demographic data and voiding diaries of these patients will be evaluated. For this purpose, patients will be divided into mainly three groups according to the anticholinergic agent used.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: